Professor Jacob George
Clinical Professor (Teaching and Research)
Molecular and Clinical Medicine, School of Medicine
+44 (0)1382 383204
Ninewells - Mailbox 2
Professor Jacob George is Professor of Cardiovascular Medicine & Therapeutics and R&D Director for the East of Scotland. He is one of four members of the NHS Research Scotland Strategy Board. Professor George is Director of the Tayside Medical Sciences Centre (TASC) comprising of the UKCRN registered Tayside Clinical Trials Unit, Clinical Research Centre, Tayside Biorepository, Clinical Research Imaging Facility, Research Governance, TASC Legal, Research Finance, Commercial and Non-Commercial Trial teams as well as the East of Scotland Research Ethics Service. He is actively involved in Medicines Governance in Scotland, being both the Chair of the Medicines Advisory Group since 2009 and Tayside representative on the Scottish Medicines Consortium (SMC) since 2010. He also sits on the National Appeals Panel for drugs not approved by the SMC. He was recently appointed by the Minister of Health, Malaysia as an International Expert Member of the Malaysian Scientific Review Panel for Phase I Clinical Trials.
Professionally, he is a Consultant Physician in qualified in Clinical Pharmacology and General Internal Medicine and is an accredited European Hypertension Specialist. His clinical interest is in managing patients with high Cardiovascular risk. He is also Professor of Cardiovascular Medicine & Therapeutics at the University of Dundee Medical School. His research interests are focused on three main areas: Understanding mechanisms how oxidative stress affects vascular biology and how it can be modified to improve clinical outcomes. He is currently Chief Investigator for the ALLAY (Allopurinol in Resistant Hypertension), ALFIE (Allopurinol in Functional Impairment in the Elderly) and VESUVIUS (effect of e-cigarette versus traditional cigarettes on vascular function) trial. In addition to this he is Principal Investigator for numerous Commercially Sponsored clinical trials. His research publications have been covered by more than 50 news organizations worldwide and he has conducted more than 80 media interviews including live television broadcasts to national and international media on the results of his research.
Lists of his various awards, local, national and international roles, grant funding and publications are contained within his CV (upon request)
The University of Dundee is leading a major new clinical trial of a drug it is hoped may help to prevent the worst ravages of COVID-19
Cigarette smokers who switch to nicotine containing vaporisers could significantly improve their vascular health, a major University of Dundee study has concluded.